Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study

Kevin R. Kelly, Sikander Ailawadhi, David S. Siegel, Leonard T. Heffner, George Somlo, Sundar Jagannath, Todd M. Zimmerman, Nikhil C. Munshi, Sumit Madan, Asher Chanan-Khan, Sagar Lonial, Suraj Chandwani, Ashot Minasyan, Markus Ruehle, Farima Barmaki-Rad, Afsaneh Abdolzade-Bavil, Faiza Rharbaoui, Eva Herrmann-Keiner, Thomas Haeder, Andrea Wartenberg-DemandKenneth C. Anderson

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study'. Together they form a unique fingerprint.

Medicine & Life Sciences